Giant cell tumour of bone
- PMID: 37121582
- DOI: 10.1302/0301-620X.105B5.BJJ-2022-1231.R1
Giant cell tumour of bone
Abstract
Giant cell tumour of bone (GCTB) is a locally aggressive lesion that is difficult to treat as salvaging the joint can be associated with a high rate of local recurrence (LR). We evaluated the risk factors for tumour relapse after treatment of a GCTB of the limbs. A total of 354 consecutive patients with a GCTB underwent joint salvage by curettage and reconstruction with bone graft and/or cement or en bloc resection. Patient, tumour, and treatment factors were analyzed for their impact on LR. Patients treated with denosumab were excluded. There were 53 LRs (15%) at a mean 30.5 months (5 to 116). LR was higher after curettage (18.4%) than after resection (4.6%; p = 0.008). Neither pathological fracture (p = 0.240), Campanacci grade (p = 0.734), soft-tissue extension (p = 0.297), or tumour size (p = 0.872) affected the risk of recurrence. Joint salvage was possible in 74% of patients overall (262/354), and 98% after curettage alone (262/267). Of 49 patients with LR after curettage, 44 (90%) underwent repeated curettage and joint salvage. For patients treated by curettage, only age less than 30 years (p = 0.042) and location in the distal radius (p = 0.043) predicted higher LR. The rate of LR did not differ whether cement or bone graft was used (p = 0.753), but may have been reduced by the use of hydrogen peroxide (p = 0.069). Complications occurred in 15.3% of cases (54/354) and did not differ by treatment. Most patients with a GCTB can undergo successful joint salvage by aggressive curettage, even in the presence of a soft-tissue mass, pathological fracture, or a large lesion, with an 18.4% risk of local recurrence. However, 90% of local relapses after curettage can be treated by repeat joint salvage. Maximizing joint salvage is important to optimize long-term function since most patients with a GCTB are young adults. Younger patients and those with distal radius tumours treated with joint-sparing procedures have a higher rate of local relapse and may require more aggressive treatment and closer follow-up.
© 2023 The British Editorial Society of Bone & Joint Surgery.
Conflict of interest statement
None declared.
References
-
- Turcotte RE , Wunder JS , Isler MH , et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study . Clin Orthop Relat Res . 2002 ; 397 ( 397 ): 248 – 258 . 10.1097/00003086-200204000-00029 , 11953616
-
- Campanacci M , Baldini N , Boriani S , Sudanese A . Giant-cell tumor of bone . J Bone Joint Surg Am . 1987 ; 69 ( 1 ): 106 – 114 . 10.2106/00004623-198769010-00018 , 3805057
-
- Gulia A , Puri A , Chorge S , Panda PK . Epidemiological data and case load spectrum of patients presenting to bone and soft tissue disease management group at a tertiary cancer center . Indian J Cancer . 2016 ; 53 ( 2 ): 333 – 338 . 10.4103/0019-509X.197734 , 28071641
-
- Guo W , Xu W , Huvos AG , Healey JH , Feng C . Comparative frequency of bone sarcomas among different racial groups . Chin Med J (Engl) . 1999 ; 112 ( 12 ): 1101 – 1104 . 11721448
-
- Skubitz KM . Giant cell tumor of bone: current treatment options . Curr Treat Options Oncol . 2014 ; 15 ( 3 ): 507 – 518 . 10.1007/s11864-014-0289-1 , 24788576
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials